ON-DEMAND: SHOWCASES AND VIRTUAL BOOTHS (available all-day)

LIVE: Keynote Address – The Future of Danish Life Science Strategy

• Providing an update on the 2018 Life Sciences Growth Plan
  
• Progress on the 36 initiatives put in place to target barriers and capitalise on opportunities across the value chain for the Danish Life Sciences Industry across the value chain
  
• How and in what ways has the covid-19 pandemic affected the sector?

LIVE: Keynote Address – The Future of Swedish Life Science Strategy

• Outlining the core components of the new Life Sciences Strategy
  
• How will Sweden work to attract and maintain life science companies and strengthen home-grown companies’ abilities to grow and meet global healthcare demands?
  
• How and in what ways will the new strategy and roadmap be implemented?

LIVE: Joint Q&A

LIVE: OPENING PANEL (40 Mins) Cultivating a sustainable ecosystem and companies with long-term ambitions in the Nordics

Key stakeholders from across the region discuss how the Nordic ecosystem is evolving and what more can be done to finance, invest and build the Nordic cluster with a great proportion of larger companies with long-term ambitions, to complement and support the thriving startup and growth stage community.

• What does it take to build large and internationally competitive companies? Do enough have the long-term ambitions?
  
• Which policy, regulation and industry initiatives can help build upon the exceptional life science leadership and innovation and work towards an even more internationally competitive hub and the growth of $billion businesses?
  
• How, and in which ways, can Government strategy and support help shape and build the Nordic life sciences cluster?
  
• What are the key success factors for companies in internationalisation and finding global investors, partners and advisors?

1:1 PARTNERING OPENS (24 Hrs)

LIVE: PUBLIC CEO FORUM (2 Hrs)

Hosted by:             

Moderator: Don deBethizy, Director, Argenx

Nordic and Global Capital Market Outlook
Adam Kostyal, SVP, Head of European Listings, Nasdaq
Peter Legind-Hansen, MD, Nasdaq

Key Legal Trends and Highlights Erik Sjöman, Partner, Vinge
Dain Hård Nevonen, Partner, Vinge

Biotech Going Digital
Nikolaj Sørensen, CEO, Orexo

KEYNOTE PANEL (45 Mins) Investing in Healthtech & Digital Health - The next wave of Nordic innovation

Healthtech and digital health technologies are starting to realise their promise and make meaningful impacts across the life science and healthcare space, and the Nordic countries are among Europe’s leaders in the digital healthcare revolution. Investors and executives discuss the local and international investment landscape in digital and health technology and how the Nordics can lead the way in innovation.

• How quickly could Nordic healthtech innovation grow to match medtech and biotech expertise?
• The region already boasts some exciting digital health success stories; is innovation in this area continuing to grow and how are
  investors seeing digital investment opportunities compared to more traditional investments?
• The covid-19 epidemic has expedited the digitisation the healthcare sector and validated its necessity; how are investors evaluating these opportunities as necessity in which specific technologies has the acceleration been most evident, and how do you pick the future winners?
  

Patrik Sobocki, Investment Manager, Industrifonden
Klaus Stöckemann, Managing Partner, Peppermint VP
Andreas Lindblom, CEO, Sciety
Karl Xavier, Partner, Axilium Capital
Moderator: Kathrine Myhre, CEO, Norway Health Tech

PANEL (1 Hr) What’s hot in early stage investment?

Expert early-stage investors highlight where they see the exciting and hot new areas before settling in as judges of the Inv¤$table Startups in Stockholm competition for the Nordic region’s life science and healthcare innovators!

• The Nordic early-stage startup ecosystem is booming–in which areas is there most excited and where is the early capital currently going?
  
• How are smaller funds competing with larger local and international funds? Will we see ever greater syndication in early deals?
  
• Is there enough support and local capital for early-stage innovation to be funded and thrive?

LIVE: PRIVATE CEO FORUM (1 Hr 45 Mins)

Hosted by:       

Moderator: Don deBethizy, Director, Argenx

Nordic and Global Capital Market Outlook
Adam Kostyal, SVP, Head of European Listings, Nasdaq
Peter Legind-Hansen, MD, Nasdaq

Accessing US Capital & Partners
Chris Jeffers, Member, Mintz

Raising Capital During COVID-19
Patric Stenberg, CEO, Gesynta

LIVE: CLOSING PANEL (45 Mins) Panel: Global syndication and expanding your international investor base

With new Nordic and European life science funds emerging, long term specialists recharging and new players and capital from Asia and the Middle East, as well as the US, increasingly entering into deals, global syndication in the healthcare space is reforming the investment landscape. Investors discuss how the Nordic region, as a leading European hub for new science and innovation, and the companies from it can access, build and leverage an international investor base.

• Will the trend of private rounds in place of IPOs in Europe for European companies continue? Do the strong Nordic public markets factor into investment decisions?
  
• Will increasing interest from American and Asian funds lead to more competitive tension for deals in Europe?
  
• How can companies, and how will investors, be getting out and connecting internationally in the new normal?

INTERACTIVE: VIRTUAL NETWORKING RECEPTION

1:1 PARTNERING RE-OPENS (24 Hrs)

LIVE: KEYNOTE PANEL (45 Mins) Coming out the other side: Perspectives on life science strategies, private and public financing partnerships and M&A in the aftermath post-COVID-19

The COVID-19 outbreak has sent shockwaves through the world, disrupting every industry and creating uncertainties in financial markets. The life sciences and healthcare is in a unique position with some companies pivoting to help in the fight against the virus, others business plans being severely disrupted, and both public and private investors in the sector navigating an untrodden path. A cross-stakeholder panel discusses

• What has been the impact on investors portfolio companies, investment strategies and appetite in the short and medium term?
  
• How and where will changes in the public and private capital available to companies affect wider industry M&A activity?
  
• Could Pharma partnering strategies change? How can companies best position themselves to come out stronger?

LIVE: CLINICAL STRATEGIES WORKSHOP (1 Hr 30 Mins)

PANEL (45 Mins) Driving shareholder value through effective partnerships

Partnering up with big pharma or other life science companies can make cost savings and pool resources and expertise, but for public companies are not without risk. Executives of public companies with licencing, co-development and R&D partnerships share their stories of securing these deals and discuss effective deal structures, mitigating risks in asset dilution and commercialisation rights and how to drive shareholder value through optimising these partnerships.

• Balancing partnerships with further capital raises for pipeline development; what are the long term affects on stock price?
  
• What are the most effective deal structures for public companies entering partnerships?
  
• How can you ensure deals are transformative for company growth whilst retaining value for shareholders?

LIVE: CLOSING PANEL (45 Mins) Developing and optimising pharma partnerships across biotech, medtech and healthtech innovation

The potentially transformative nature of partnership a big pharma is well documented but is not without its risks and challenges and partnerships and deals differ between private and public companies. Pharma continue to be hungry to source innovation and build win-win partnerships with the latest technologies to supplement and complement internal R&D. Heads of innovation, search and evaluation and business development from big Pharma discuss the role pharma companies are taking in supporting younger companies and the evolving strategies in all life science and technology partnerships and deals.

• Will the trend of private rounds in place of IPOs in Europe for European companies continue? Do the strong Nordic public markets factor into investment decisions?
  
• Will increasing interest from American and Asian funds lead to more competitive tension for deals in Europe?
  
• How can companies, and how will investors, be getting out and connecting internationally in the new normal?

INTERACTIVE: VIRTUAL SYNDICATION RECEPTION

1:1 PARTNERING RE-OPENS (24 Hrs)

1:1 PARTNERING RE-OPENS (24 Hrs)